Yemaachi Biotechnology Launches The African Cancer Atlas, in Partnership with Roche
Roche has signed as the founding partner to initiate the consortium which will generate genomic and clinical data from up to 7,500 African cancer patients ACCRA, Ghana & WASHINGTON–(BUSINESS WIRE)–Yemaachi Biotech, a pioneering genomics research company based in Ghana, announced today a partnership with Roche to launch The African Cancer Atlas (TACA). This initiative aims […]
Liquid Biopsy – The necessary first step towards democratising precision oncology?
While IHC and imaging are useful for diagnosing and staging cancers, they are limited in their ability to inform clinical decision-making regarding the use of increasingly available targeted therapies that are revolutionising cancer care in developed countries. For this, more advanced molecular tests are required, and next generation sequencing-based liquid biopsy tests are at the cutting edge.
African biotech holds the key to transforming not just the health of African people, but our economies as well
Why has over a decade of political rhetoric and unprecedented donor support for scientific capacity building not translated into more tangible scientific output?
A closer look reveals a glaring gap in the current structure of the scientific ecosystem in Africa – the almost complete absence of the private sector.
Ghana startup strives for greater African representation in cancer research
As one of Ghana’s only labs equipped for molecular analysis, Bediako’s team have tasked themselves with collecting data they believe will advance the development of medicine for cancer patients throughout the continent and diaspora
Yemaachi Biotech, Lucence Aim to Improve Genomic Breast Cancer Testing in Ghana and Beyond
GenomeWeb covers Yemaachi’s collaboration with cancer liquid biopsy firm Lucence to document and characterize the genomics of breast cancer in women of African descent.
“The Scientist” Feature: Quest for Research Freedom Fuels African Biotech Boom
Tired of dancing to the tunes of international funders, and doubtful that long-promised national grants will come, a handful of African biomedical scientists have turned to private investors to bankroll their dreams of autonomy in the lab
H3D Partners with Yemaachi to Utilise African Genetic Diversity to Develop New Tools for Improving Treatment Outcomes for the African Patient Populations
The Holistic Drug Discovery and Development (H3D) Centre at the University of Cape Town (UCT) has entered into a strategic partnership with Yemaachi Biotech, to exploit African genetic diversity by identifying new therapies and platforms that optimize cancer treatments for African patient populations.